Safety of triflusal (antiplatelet drug) in patients with aspirin-exacerbated respiratory diseases

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 63, Issue 1, 2008, Pages 112-115

  Fraj, J ^b   Valero, A ^c,d   Vives, R ^e   Perez I ^f   Borja, J ^f   Izquierdo, I ^f   Picado, C ^a,c,d  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^f J Uriach y Compania   (Spain)

Author keywords

AIA; Antiplatelet agents; Aspirin exacerbated respiratory disease; Asthma; Cyclo oxygenase; Triflusal

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHISTAMINIC AGENT; ANTITHROMBOCYTIC AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; DICLOFENAC; DIPYRONE; GLUCOCORTICOID; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; TRIFLUSAL;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; ASPIRIN EXACERBATED RESPIRATORY DISEASE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; FEMALE; HUMAN; LUNG FUNCTION; LUNG FUNCTION TEST; MALE; PRIORITY JOURNAL; PROVOCATION TEST; RESPIRATORY TRACT DISEASE; SINGLE BLIND PROCEDURE; SYMPTOM;

ADMINISTRATION, ORAL; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; ASTHMA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG HYPERSENSITIVITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROBABILITY; REFERENCE VALUES; RESPIRATORY FUNCTION TESTS; RISK ASSESSMENT; SALICYLATES; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 36649028299     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2007.01473.x     Document Type: Article

References (30)

1. Stevenson DD, Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol 2006 118 : 773 786.
2. Picado C, Castillo JA, Montserrat JM, Agustí-Vidal A. Aspirin intolerance as a precipitating factor of life-threatening attacks of asthma requiring mechanical ventilation. Eur Respir J 1989 2 : 127 129.
3. Plaza V, Serrano J, Picado C, Sanchis J. Frequency and clinical characteristics of rapid-onset fatal and near-fatal asthma. Eur Respir J 2002 19 : 846 852.
4. Picado C. Mechanisms of aspirin sensitivity. Curr Allergy Asthma Rep 2006 6 : 198 202.
5. Picado C, Fernandez-Morata JC, Juan M, Roca-Ferrer J, Fuentes M, Xaubet A et al. Cyclooxygenase-2 mRNA is downexpressed in nasal polyps from aspirin-sensitive asthmatics. Am Rev Respir Dis 1999 160 : 291 296.
6. Pujols L, Mullol J, Alobid I, Roca-Ferrer J, Xaubet A, Picado C. Dynamics of COX-2 in nasal mucosa and nasal polyps from aspirin-tolerant and aspirin-intolerant patients with asthma. J Allergy Clin Immunol 2004 114 : 814 819.
7. Perez-Novo CA, Watelet JB, Claeys C, Van Cauwenberge P, Bachert C. Prostaglandin, leukotriene and lipoxin balance in chronic rhinosinusitis with and without nasal polyps. J Allergy Clin Immunol 2005 115 : 1189 1196.
8. Kowalski ML, Pawliczak R, Wozniak J, Siuda K, Poniatowka M, Iwaszkiwicz J et al. Differential metabolism of arachidonic acid in nasal polyps epithelial cells cultured from aspirin-sensitive and aspirin-tolerant patients. Am J Respir Crit Care Med 2000 161 : 391 398.
9. 2 production by bronchial fibroblasts of asthmatic patients, with special reference to aspirin-induced asthma. J Allergy Clin Immunol 2003 111 : 1041 1048.
10. Roca-Ferrer J, Pujols L, Gartner S, Moreno A, Pumarola F, Mullol J et al. Upregulation of COX-1 and COX-2 in nasal polyps in cystic fibrosis. Thorax 2006 61 : 592 596.
11. Christie PE, Tagari P, Ford-Hutchinson AW, Black C, Markendorf A, Schmitz-Schumann M et al. Urinary leukotriene E4 after lysine-aspirin inhalation in asthmatic subjects. Am Rev Respir Dis 1992 146 : 1531 1534.
12. Sladek K, Dworski R, Soja J, Sheller JR, Nizankowska E, Oates JA et al. Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with asthma after aspirin challenge. Am J Respir Crit Care Med 1994 149 : 940 946.
13. Picado C, Ramis I, Rosello J, Prat J, Bulbena O, Plaza V et al. Release of peptide leukotriene into nasal secretions after local instillation of aspirin in aspirin-sensitive asthmatic patients. Am Rev Respir Dis 1992 145 : 65 69.
14. Cowburn AS, Sladek K, Soja J, Adamek L, Nizankowska E, Szczeklik A et al. Overexpresion of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 1998 101 : 834 846.
15. Picado C, Valero A. COX-1 sparing drugs in aspirin-sensitive asthmatics. Clin Exp Allergy 2001 31 : 179 181.
16. Sestini P, Armetti L, Gambaro G, Pieroni MG, Refini RM, Sala A et al. Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma. Am J Respir Crit Care Med 1996 153 : 572 575.
17. Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina - summary article. J Am Coll Cardiol 2002 41 : 159 168.
18. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. Executive summary. Circulation 2004 110 : 588 636.
19. Adams H, Adams R, Del Zoppo G, Goldstein RB. Guidelines for the early management of patients with ischemic stroke. Stroke 2003;34:1056-1083. 2005 Guidelines update. Stroke 2005 36 : 916 921.
20. Cruz-Fernández JM, López-Bescós L, García-Dorado D, López García-Aranda V, Cabadés A, Martín-Jadraque L et al. Randomized comparative trial of triflusal and aspirin following acute myocardial infarction. Eur Heart J 2000 21 : 457 465.
21. Matías-Guiu J, Ferro JM, Alvarez-Sabín J, Torres F, Jiménez MD, Lago A et al. Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction. Stroke 2003 34 : 840 848.
22. Costa J, Ferro JM, Matías-Guíu J, Alvarez-Sabin J, Torres F. Triflusal for preventing serious vascular events in people at high risk. Cochrane Database Syst Rev 2005 : CD004296.pub2.
23. Fernández de Arriba A, Cavalcanti F, Miralles A, Bayon I, Alonso A, Merlos M et al. Inhibition of cyclooxygenase-2 expression by 4-trifluoromethyl derivatives of salicylate, triflusal and its deacetylated metabolite, 2-hydroxy-4-trifluoromethylbenzoic acid. Mol Pharmacol 1999 55 : 753 760.
24. Casadevall J, Ventura PJ, Mullol J, Picado C. Intranasal challenge with aspirin in the diagnosis of aspirin intolerant asthma: evaluation of nasal response by acoustic rhinometry. Thorax 2000 55 : 921 924.
25. Melillo G, Balzano G, Bianco S, Dahlen B, Godard P, Kowalsky ML et al. Report of INTERASMA working group on standardization of inhalation provocation tests in aspirin-induced asthma. Oral and inhlation provocations tests for the diagnosis of aspirin-induced asthma. Allergy 2001 56 : 899 911.
26. Sacco RL, Adams RA, Albers G, Alberts MJ, Benavente O, Furie K et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack. Stroke 2006 37 : 577 617.
27. De Castellarnau C, Sancho MJ, Albors M. Effects and interaction studies of triflusal and other salicylic acid derivatives on cyclooxygenase in rats. Prostaglandins Leukot Essent Fatty Acids 1988 31 : 83 89.
28. Rindeau D, Percival MD, Brideua C. Etoricoxib (MK-0663): preclinical profila and comparison with other agents that selectively inhibit cyclooxygenases-2. J Pharmacol Exp Ther 2001 296 : 556 558.
29. Mastalerz L, Sanak M, Gawlewicz A, Gielicz A, Faber J, Szczeklik A. Different eicosanoid profile of the hypersensitivity reactions triggered by aspirin and celecoxib in a patient with sinusitis, asthma, and urticaria. J Allergy Cin Immunol 2006 118 : 957 958.
30. Looney Y, O'Shea A, O'Dwyer R. Severe bronchospasm after parenteral paracoxib. Cycloxygenase-2 inhibitors: not the answer yet. Anesthesiology 2005 102 : 473 475.